Charles Vogel

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Vinorelbine 21%
3. Neoplasms 19%
4. Trastuzumab 18%
5. Drug Therapy 18%
6. Doxorubicin 17%
7. Cyclophosphamide 17%
8. Therapeutics 17%
9. Hepatocellular Carcinoma 15%
10. human ERBB2 protein 14%
11. Tamoxifen 14%
12. Fluorouracil 13%
13. Survival 12%
14. Anthracyclines 10%
15. Kaposi's Sarcoma 10%
16. liposomal doxorubicin 10%
17. Megestrol Acetate 10%
18. Toremifene 10%
19. Estrogen Receptors 9%
20. Safety 9%
21. Adjuvant Chemotherapy 9%
22. Uganda 9%
23. Clinical Trials 8%
24. Hormones 8%
25. Vincristine 8%
26. Appointments and Schedules 8%
27. Agranulocytosis 8%
28. Hepatitis Antigens 8%
29. Capecitabine 8%
30. Docetaxel 7%
31. Aromatase Inhibitors 7%
32. Combination Drug Therapy 7%
33. Anastrozole 7%
34. Dexrazoxane 7%
35. Serum 6%
36. Group Psychotherapy 6%
37. Methotrexate 6%
38. Phase II Clinical Trials 6%
39. Pharmacokinetics 6%
40. Bone and Bones 6%
41. Levamisole 6%
42. Estrogens 6%
43. Zoledronic Acid 5%
44. Clinical Trials, Phase I 5%
45. Neoplasm Metastasis 5%
46. Mitoxantrone 5%
47. imidazole 5%
48. alpha-Fetoproteins 5%
49. Paclitaxel 5%
50. Taxoids 5%